# Violet Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/violet-therapeutics

- Industry: Biotechnology
- Headquarters: Somerville, US
- Website: www.violettx.com/
- Total disclosed funding: $12M
- Latest round: Seed (May 13, 2026)
- Investors on record: 5

## About

Based in the US, Violet Therapeutics, Inc. operates as a biotechnology company that engages in the research and development of drugs for treating diseases of the central nervous system and other neurodegeneration diseases.

Founded in 2021 by Mass General Brigham Ventures in collaboration with Francisco J. Quintana and others, and based in Massachusetts, US, Violet Therapeutics, Inc. operates as a biopharmaceutical company that engages in the research and development of cellular therapeutics for the treatment of the central nervous system and other diseases. In May 2026, Violet Therapeutics, Inc. raised USD 4.75 million in seed funding led by LifeSpan Vision Ventures, with participation from SV Health Investors, University of Tokyo Edge Capital Partners, Ono Venture Investment, and Mass General Brigham Ventures.

The company works with pharmaceutical and biotechnology organizations to provide cell-to-cell communication mapping technologies and therapeutic discovery programs for central nervous system diseases. The company utilizes proprietary platforms, including its CONNECT and C-to-C Engine technologies, to identify signaling pathways involved in neuroinflammation, neurodegeneration, and synaptic dysfunction. Its lead program targets EphB3, a receptor tyrosine kinase implicated in microglia-astrocyte interactions associated with neurological disorders. Violet’s multidisciplinary team of neuroscientists, biologists, bioinformaticians, and drug discovery specialists develops novel therapeutic candidates for conditions such as Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders.

The company’s revenue is generated by advancing proprietary therapeutic programs and drug discovery technologies focused on neurodegenerative diseases. Its business model is supported through biotechnology partnerships, strategic research collaborations, licensing opportunities, and venture-backed platform development activities. Violet develops proprietary intellectual property around cell-to-cell communication mapping and therapeutic targets discovered through its platforms. As programs progress toward clinical development, the company may derive value from licensing agreements, co-development arrangements, and potential commercialization partnerships with pharmaceutical and biotechnology organizations.

The company will use the June 2026 funding to advance its lead small-molecule program targeting EphB3 and support IND-enabling development activities.

## Funding rounds

- Seed, May 13, 2026, $4.8M — University of Tokyo Edge Capital Partners, SV Health Investors, Mass General Brigham Ventures, Ono Venture Investment, LifeSpan Vision Ventures
- Seed, Apr 20, 2023, $7.5M — University of Tokyo Edge Capital Partners, SV Health Investors, Mass General Brigham Ventures, Ono Venture Investment

## Investors

- University of Tokyo Edge Capital Partners (https://capitalatlas.ai/funds/university-of-tokyo-edge-capital-partners) — Seed
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Seed
- Mass General Brigham Ventures (https://capitalatlas.ai/funds/mass-general-brigham-ventures) — Seed
- Ono Venture Investment (https://capitalatlas.ai/funds/ono-venture-investment) — Seed
- LifeSpan Vision Ventures (https://capitalatlas.ai/funds/lifespan-vision-ventures) — Seed